Sunday , October 22 2017
Home / Therapies / SGLT-2 Therapy Center (page 14)

SGLT-2 Therapy Center

Diabetes in Control is pleased to provide you with the latest insights and information on the Sodium-Dependent Glucose Transporter Two (SGLT-2) drug class to help optimize your practice. We hope you’ll benefit from the insights and share them with your colleagues. Thanks for all you’re doing to improve your patients’ lives and longevity!

FDA Approves Xigduo XR, a New Dapagliflozin-Metformin Combination

The once-daily oral tablet is the first in the U.S. to combine the SGLT-2 inhibitor dapagliflozin with the biguanide extended-release (XR) metformin hydrochloride.. The US Food and Drug Administration (FDA) has approved a once-daily combination of dapagliflozin and metformin hydrochloride extended-release (Xigduo XR, AstraZeneca) for the treatment of adults with ...

Read More »

SGLT2 Inhibitors as Add-On for Poorly Controlled Patients on DPP-4s and Metformin

www.diabetesincontrol.com_images_Mastery_Series_2014_09_se-sglt2-201409

As the diabetes epidemic continues to grow, practitioners are increasingly searching for medication solutions that can help patients to better manage their diabetes. This month, we have a recent slides series from the ADA showing the positive effects of adding-on SGLT-2 inhibitors to the medication regimen of patients on DPP-4’s ...

Read More »